CN111990574A - L-carnitine nutritional effervescent tablet - Google Patents

L-carnitine nutritional effervescent tablet Download PDF

Info

Publication number
CN111990574A
CN111990574A CN202010989186.3A CN202010989186A CN111990574A CN 111990574 A CN111990574 A CN 111990574A CN 202010989186 A CN202010989186 A CN 202010989186A CN 111990574 A CN111990574 A CN 111990574A
Authority
CN
China
Prior art keywords
carnitine
vitamin
parts
effervescent tablet
nutritional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010989186.3A
Other languages
Chinese (zh)
Inventor
何连顺
李斌水
马静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jing Jing Pharmaceutical Co ltd
Inner Mongolia Jingjing Biological Technology Co ltd
Original Assignee
Jing Jing Pharmaceutical Co ltd
Inner Mongolia Jingjing Biological Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jing Jing Pharmaceutical Co ltd, Inner Mongolia Jingjing Biological Technology Co ltd filed Critical Jing Jing Pharmaceutical Co ltd
Priority to CN202010989186.3A priority Critical patent/CN111990574A/en
Publication of CN111990574A publication Critical patent/CN111990574A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/40—Effervescence-generating compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention discloses an L-carnitine nutritional effervescent tablet which is prepared from the following components in parts by weight: 40-90 parts of L-carnitine citric acid, 7-15 parts of acesulfame, 10-50 parts of sodium bicarbonate, 5-35 parts of acid agent, 3-15 parts of cane sugar, 0.05-0.2 part of vitamin C and/or E, 0.05-5 parts of edible essence, 0.3-0.8 part of lubricant and adhesive. The preparation process of the L-carnitine nutritious effervescent tablet has the advantages of simple operation process, high L-carnitine content, quick dissolution of the effervescent tablet, good taste and suitability for preparing the L-carnitine nutritious effervescent tablet.

Description

L-carnitine nutritional effervescent tablet
Technical Field
The invention belongs to the field of nutritional additives, and particularly relates to an L-carnitine nutritional effervescent tablet.
Background
L-carnitine (also called L-carnitine or transliteration carnitine), and red meat is the main source of L-carnitine and has no toxic and side effects on human bodies. Different types of diets already contain 5-100 mg of l-carnitine, but generally only 50 mg per day can be ingested by people from the diet, and less by vegetarians. The main physiological function of the L-carnitine is to promote the conversion of fat into energy, and the L-carnitine can reduce body fat and weight without reducing water and muscle. The L-carnitine crystals are very hygroscopic and therefore need to be handled during use.
L-carnitine is an energy substance for sperm maturation and has the function of improving the number and the vitality of sperms. The survey of 30 adult men shows that the number and the vitality of sperms are in direct proportion to the supply amount of the L-carnitine in the diet within a certain range, and the content of the L-carnitine in the sperms is in positive correlation with the content of the L-carnitine in the diet. The research of Watanabe et al finds that L-carnitine can improve the tolerance of a disease patient in practice, such as the practice time, the maximum oxygen absorption, the lactic acid threshold, the oxygen absorption threshold and other indexes, and can be improved to different degrees after the body is supplemented with the L-carnitine; oral administration of L-carnitine also can improve the muscle tolerance of maximum oxygen absorption by 80%, shorten the recovery period after strenuous exercise, and reduce the tension and fatigue caused by exercise.
Because L-carnitine participates in the myocardial fat metabolism process, the medicine can resist arrhythmia caused by ischemia and improve the tolerance of coronary heart disease patients to beat stimulation. Has important effect on fat metabolism and energy supply in animals, once the animals are inhibited from synthesizing carnitine in vivo or excessive in carnitine discharge and relief, or the enzymatic activity of a carnitine transfer system is reduced and lost, the lipid metabolism of the body is disturbed, the energy supply is insufficient, and a series of related diseases are caused. At present, L-carnitine is mainly used as a medicine clinically for treating heart failure, shock, lowering blood pressure, losing weight, treating cardiovascular diseases and the like.
In addition, L-carnitine also has good curative effect on nervous system diseases, diabetes and complications caused by diabetes. The L-carnitine derivatives also have important functions, and can improve the functions of cardiac muscle, retina and peripheral nerves; can be used for preventing and treating cardiovascular and cerebrovascular diseases, hypomnesis, Alzheimer disease, and Parkinson disease. Recent research also finds that the L-carnitine and the derivatives thereof can be used for treating and preventing heart blood filling, dilated chronic heart disease and chronic fatigue syndrome and enhancing the immunity of AIDS patients.
The L-carnitine can obviously reduce the weight of the human body and has extremely high safety. L-carnitine is popular as a weight-losing and sports food in Europe and America, and the product is sold well. L-carnitine is also listed as a nutrition enhancer by the Ministry of health of China, and weight-losing nutriments such as Kangzhimei, Kangliting and the like produced by imported L-carnitine are also provided in Guangzhou and other places.
However, the solubility of the L-carnitine in water is 2500g/L (20 ℃), the hygroscopicity is very strong, and the L-carnitine is very easy to be wetted or even dissolved by moisture in a natural state, so that the stable L-carnitine is constructed, and the application value is very important. Chinese patent CN102715394A provides an L-carnitine effervescent tablet, which comprises beet red juice powder, fructo-oligosaccharide, L-carnitine tartrate, citric acid, sodium bicarbonate, sorbitol, edible essence, aspartame, acesulfame potassium, fumaric acid, magnesium stearate and the like, wherein the content of the L-carnitine serving as an effective component in the effervescent tablet is less than 10%, and the used aspartame is not resistant to high temperature and has disadvantages in the using process. In order to solve the existing problems, the invention provides a novel effervescent tablet preparation method.
Disclosure of Invention
The invention provides the L-carnitine nutritious effervescent tablet which has the advantages of simple preparation process and operation process, high L-carnitine content, quick dissolution and good taste.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the L-carnitine nutritional effervescent tablet comprises the following components in parts by weight: 40-90 parts of L-carnitine citric acid, 7-15 parts of acesulfame, 10-50 parts of sodium bicarbonate, 5-35 parts of acid agent, 3-15 parts of cane sugar, 0.05-0.2 part of vitamin C and/or E, 0.05-5 parts of edible essence, 0.3-0.8 part of lubricant and adhesive.
Further, the acid agent is one or more of catechin, citric acid, tartaric acid, taurine, fumaric acid, and amino acid.
Further, the adhesive is absolute ethyl alcohol, the weight of the absolute ethyl alcohol accounts for 8-10% of the total weight, and the total weight is the sum of the weight of the L-carnitine citric acid, the acesulfame, the sodium bicarbonate, the acid agent, the sucrose, the vitamin C and/or E, the edible essence and the lubricant.
Further, the lubricant is one or more of polyethylene glycol, magnesium stearate, polyvinyl pyrrolidone and dodecyl trimethyl ammonium chloride.
Further, when the components in parts by weight contain both vitamin C and vitamin E, the part ratio of the vitamin C to the vitamin E is 8-10: 1.
Further, the preparation method comprises the following steps: step one, dry-mixing L-carnitine citric acid, vitamin C and/or E, sodium bicarbonate, an acid agent, acesulfame potassium, cane sugar, a lubricant and edible essence for 15-30 minutes;
step two, adding an adhesive to perform wet mixing granulation, and then drying;
and step three, carrying out whole-particle crushing on the dry powder particles at the indoor humidity of below 35 degrees, controlling the particle size to be below 150um, and tabletting to obtain the effervescent tablets.
As the invention adopts the invention, compared with the prior art, the invention has the technical progress that: the preparation method comprises the steps of dry-mixing L-carnitine citric acid, vitamin C and/or E, sodium bicarbonate, an acid agent, acesulfame potassium, cane sugar and edible essence in a formula for 15-30 minutes, adding a lubricant and an adhesive for wet mixing granulation, drying, carrying out granule size stabilization and crushing on obtained dry powder granules under the condition that the indoor humidity is controlled to be below 35 ℃, controlling the granules to be below 150 mu m, and carrying out tabletting to obtain effervescent tablets; in conclusion, the preparation process of the L-carnitine nutritious effervescent tablet has simple operation process, high L-carnitine content, quick dissolution of the effervescent tablet and good taste, and is suitable for preparing the L-carnitine nutritious effervescent tablet.
Detailed Description
The following description is given in conjunction with preferred embodiments of the present invention. It should be understood that the preferred embodiments described herein are for purposes of illustration and explanation only and are not intended to limit the present invention.
Example 1
In the embodiment, 90g of L-carnitine citric acid, 15g of acesulfame potassium, 50g of sodium bicarbonate, 35g of tartaric acid, 15g of sucrose, 0.2g of vitamin C, 0.5g of edible essence and 0.8g of polyethylene glycol are accurately weighed; fully mixing the above material formula for 15 minutes, spraying absolute ethyl alcohol accounting for 8% of the total weight of the materials after uniformly mixing, then carrying out wet granulation, after the granulation is finished, carrying out hollow drying until the drying weight loss is 0.5%, then sampling 5g and fixing the volume to 25ml, detecting that the pH value is qualified when the pH value is between 4.2 and 7.4, otherwise, adjusting by using tartaric acid or citric acid as an acid agent, and preferably, the pH value is between 5.5 and 6.0; and (3) granulating after the pH value is qualified, preferably granulating and crushing dry powder particles below 35 ℃ in indoor humidity, controlling the particle size below 150um, metering the total weight to be 201.5g, adjusting an automatic tablet press, carrying out die punching and tabletting according to 4g of each tablet, and carrying out plastic packaging after tabletting to obtain a finished product.
Example 2
In the embodiment, 90g of L-carnitine citric acid, 15g of acesulfame potassium, 50g of sodium bicarbonate, 35g of catechin, 15g of sucrose, 0.2g of vitamin E, 5g of edible essence and 0.8g of magnesium stearate are accurately weighed; fully mixing the above material formula for 20 minutes, spraying absolute ethyl alcohol accounting for 8% of the total weight of the materials after uniform mixing, then carrying out wet granulation, after the granulation is finished, carrying out hollow drying until the drying weight loss is 0.5%, then sampling 5g and fixing the volume to 25ml, detecting that the pH value is qualified when the pH value is between 4.2 and 7.4, otherwise, adjusting by using acid agent catechin, and preferably, the pH value is between 5.5 and 6.0; and (3) granulating after the pH value is qualified, preferably granulating and crushing dry powder particles below 35 ℃ in indoor humidity, controlling the particle size below 150um, metering the total weight to 206g, adjusting an automatic tablet press, carrying out die punching and tabletting according to 4g of each tablet, and carrying out plastic packaging after tabletting to obtain a finished product.
Example 3
In this example, 90g of l-carnitine citric acid, 15g of acesulfame potassium, 50g of sodium bicarbonate, 17.5g of aspartic acid, 17.5g of taurine, 15g of sucrose, 0.18g of vitamin C, 0.02g of vitamin E, 3g of edible essence, 0.3g of magnesium stearate and 0.5g of dodecyl trimethyl ammonium chloride are accurately weighed; fully mixing the above material formula for 15 minutes, spraying absolute ethyl alcohol accounting for 9 percent of the total weight of the materials after uniform mixing, then carrying out wet granulation, after the granulation is finished, carrying out hollow drying until the drying weight loss is 0.5 percent, then sampling 5g and fixing the volume to 25ml, detecting that the pH value is qualified when the pH value is between 4.2 and 7.4, otherwise, using aspartic acid or taurine for regulation, and preferably selecting the pH value to be between 5.5 and 6.0; and (3) granulating after the pH value is qualified, preferably granulating and crushing dry powder particles below 35 ℃ in indoor humidity, controlling the particle size below 150um, metering the total weight to be 204g, adjusting an automatic tablet press, carrying out die punching and tabletting according to 4g of each tablet, and carrying out plastic packaging after tabletting to obtain a finished product.
Example 4
In the embodiment, 4kg of L-carnitine citric acid, 0.7kg of acesulfame potassium, 1kg of sodium bicarbonate, 0.5kg of fumaric acid, 0.5kg of taurine, 0.3kg of sucrose, 0.05kg of vitamin C and 0.05kg of edible essence are accurately weighed, and the weight of polyethylene glycol is 0.03 kg; fully mixing the above material formula for 20 minutes, spraying absolute ethyl alcohol with the weight being 10% of the total weight of the material after uniform mixing, then carrying out wet granulation, carrying out vacuum drying weight loss of 0.5% after granulation is finished, then sampling 5g and fixing the volume to 25ml, detecting that the pH value is qualified when the pH value is between 4.2 and 7.4, otherwise, adjusting by using acid agents taurine and fumaric acid, and preferably, the pH value is between 5.5 and 6.0; and (3) granulating after the pH value is qualified, preferably granulating and crushing dry powder particles below 35 ℃ in the indoor humidity, controlling the particle size to be below 150um, measuring the total weight to be 7.125kg, adjusting an automatic tabletting machine, performing stamping and die pressing on tablets according to 4g per tablet, and performing plastic packaging after tabletting to obtain a finished product.
Example 5
In this example, 4kg of L-carnitine citric acid, 0.7kg of acesulfame potassium, 1kg of sodium bicarbonate, 1kg of citric acid, 0.3kg of sucrose, 0.05kg of vitamin E, 0.05kg of flavoring essence and 0.03kg of polyvinylpyrrolidone are accurately weighed; fully mixing the above material formula for 25 minutes, spraying absolute ethyl alcohol accounting for 10% of the total weight of the materials after uniformly mixing, then carrying out wet granulation, carrying out vacuum drying after the granulation is finished until the drying weight loss is 0.5%, then sampling 5g and fixing the volume to 25ml, and determining that the product is qualified when the detected pH value is between 4.2 and 7.4, otherwise, adjusting the product by using citric acid as an acid agent, and preferably, the pH value is between 5.5 and 6.0; and (3) granulating after the pH value is qualified, preferably granulating and crushing dry powder particles below 35 ℃ in the indoor humidity, controlling the particle size to be below 150um, measuring the total weight to be 7.125kg, adjusting an automatic tabletting machine, performing stamping and die pressing on tablets according to 4g per tablet, and performing plastic packaging after tabletting to obtain a finished product.
Example 6
In the embodiment, 90g of L-carnitine citric acid, 10g of acesulfame potassium, 40g of sodium bicarbonate, 15g of tartaric acid, 10g of sucrose, 0.18g of vitamin C, 0.02 of vitamin E, 0.3g of edible essence and 0.5g of polyethylene glycol are accurately weighed; fully mixing the above material formula for 30 minutes, spraying absolute ethyl alcohol accounting for 10% of the total weight of the materials after uniformly mixing, then carrying out wet granulation, carrying out vacuum drying until the drying weight loss is 0.5% after the granulation is finished, then sampling 5g and fixing the volume to 25ml, detecting that the pH value is qualified when the pH value is between 4.2 and 7.4, otherwise, adjusting by using tartaric acid or citric acid as an acid agent, and preferably, the pH value is between 5.5 and 6.0; and (3) granulating after the pH value is qualified, preferably granulating and crushing dry powder particles below 35 ℃ in the indoor humidity, controlling the particle size below 150um, metering the total weight to be 161g, adjusting an automatic tablet press, carrying out die punching and tabletting according to 4g of each tablet, and carrying out plastic packaging after tabletting to obtain a finished product.
Example 7
In the embodiment, 90g of L-carnitine citric acid, 10g of acesulfame potassium, 40g of sodium bicarbonate, 15g of tartaric acid, 10g of sucrose, 0.2g of vitamin C, 1g of edible essence and 0.5g of polyethylene glycol are accurately weighed; fully mixing the above material formula for 30 minutes, spraying absolute ethyl alcohol accounting for 10% of the total weight of the materials after uniformly mixing, then carrying out wet granulation, carrying out vacuum drying until the drying weight loss is 0.5% after the granulation is finished, then sampling 5g and fixing the volume to 25ml, detecting that the pH value is qualified when the pH value is between 4.2 and 7.4, otherwise, adjusting by using tartaric acid or citric acid as an acid agent, and preferably, the pH value is between 5.5 and 6.0; and (3) granulating after the pH value is qualified, preferably granulating and crushing dry powder particles below 35 ℃ in the indoor humidity, controlling the particle size below 150um, measuring the total weight to 161.7g, adjusting an automatic tablet press, carrying out die punching and tabletting according to 4g of each tablet, and carrying out plastic packaging after tabletting to obtain a finished product.
The adhesive used in the above embodiment is absolute ethyl alcohol, the weight of the absolute ethyl alcohol accounts for 8-10% of the total weight of the materials, wherein the total weight of the materials is the sum of the weight of L-carnitine citric acid, acesulfame potassium, sodium bicarbonate, an acid agent, sucrose, vitamin C and/or E, a flavoring essence and a lubricant.
Dissolving 1 tablet of the effervescent tablet obtained by pressing in 250ml of warm water, and drinking after complete dissolution; has sweet and delicious taste and pleasant fragrance.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the scope of the claims of the present invention.

Claims (6)

1. The L-carnitine nutritional effervescent tablet is characterized by comprising the following components in parts by weight: 40-90 parts of L-carnitine citric acid, 7-15 parts of acesulfame, 10-50 parts of sodium bicarbonate, 5-35 parts of acid agent, 3-15 parts of cane sugar, 0.05-0.2 part of vitamin C and/or vitamin E, 0.05-5 parts of edible essence, 0.3-0.8 part of lubricant and adhesive.
2. The nutritional effervescent tablet of L-carnitine as claimed in claim 1, which is characterized in that: the acid agent is one or more of catechin, citric acid, tartaric acid, taurine, fumaric acid, and amino acids.
3. The nutritional effervescent tablet of L-carnitine as claimed in claim 1, which is characterized in that: the adhesive is absolute ethyl alcohol, the weight of the absolute ethyl alcohol accounts for 8-10% of the total weight, and the total weight is the sum of the weight of L-carnitine citric acid, acesulfame potassium, sodium bicarbonate, an acid agent, sucrose, vitamin C and/or vitamin E, edible essence and a lubricant.
4. The nutritional effervescent tablet of L-carnitine as claimed in claim 1, which is characterized in that: the lubricant is one or more of polyethylene glycol, magnesium stearate, polyvinyl pyrrolidone and dodecyl trimethyl ammonium chloride.
5. The nutritional effervescent tablet of L-carnitine as claimed in claim 1, which is characterized in that: when the vitamin C and the vitamin E are simultaneously contained, the part ratio of the vitamin C to the vitamin E is 8-10: 1.
6. The nutritional effervescent tablet of L-carnitine as claimed in claim 1, which is characterized in that: the preparation method comprises the following steps:
step one, dry-mixing L-carnitine citric acid, vitamin C and/or vitamin E, sodium bicarbonate, an acid agent, acesulfame potassium, sucrose, a lubricant and edible essence for 15-30 minutes;
step two, adding an adhesive to perform wet mixing granulation, and then drying;
and step three, carrying out whole-particle crushing on the dry powder particles at the indoor humidity of below 35 degrees, controlling the particle size to be below 150um, and tabletting to obtain the effervescent tablets.
CN202010989186.3A 2020-09-18 2020-09-18 L-carnitine nutritional effervescent tablet Pending CN111990574A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010989186.3A CN111990574A (en) 2020-09-18 2020-09-18 L-carnitine nutritional effervescent tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010989186.3A CN111990574A (en) 2020-09-18 2020-09-18 L-carnitine nutritional effervescent tablet

Publications (1)

Publication Number Publication Date
CN111990574A true CN111990574A (en) 2020-11-27

Family

ID=73475613

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010989186.3A Pending CN111990574A (en) 2020-09-18 2020-09-18 L-carnitine nutritional effervescent tablet

Country Status (1)

Country Link
CN (1) CN111990574A (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071874A (en) * 1989-06-14 1991-12-10 Lonza Ltd. L-carnitine magnesium citrate
WO2005123108A2 (en) * 2004-06-09 2005-12-29 William Feinstein Advanced vitamins and protein based nutritional supplements
CN101262780A (en) * 2005-07-14 2008-09-10 希尔氏宠物营养品公司 Method for prolonging the life of animals
CN101269039A (en) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 Levorotation carnitine sustained-release dropping pill and preparation method thereof
WO2009071954A1 (en) * 2007-12-07 2009-06-11 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Effervescent tablets and effervescent granules containing carnitine tartrate
WO2011072320A1 (en) * 2009-12-14 2011-06-23 Jubilent Global Limited Effervescent l-carnitine-based composition
CN102715394A (en) * 2012-07-09 2012-10-10 宣城柏维力生物工程有限公司 L-carnitine effervescent tablet
EP2508179A1 (en) * 2011-04-05 2012-10-10 Lonza Ltd. Use of L-Carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function
CN107319242A (en) * 2017-07-20 2017-11-07 郑州博凯医药保健品有限公司 L-cn effervescent tablet for slimming and preparation method thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071874A (en) * 1989-06-14 1991-12-10 Lonza Ltd. L-carnitine magnesium citrate
WO2005123108A2 (en) * 2004-06-09 2005-12-29 William Feinstein Advanced vitamins and protein based nutritional supplements
CN101262780A (en) * 2005-07-14 2008-09-10 希尔氏宠物营养品公司 Method for prolonging the life of animals
WO2009071954A1 (en) * 2007-12-07 2009-06-11 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Effervescent tablets and effervescent granules containing carnitine tartrate
CN101269039A (en) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 Levorotation carnitine sustained-release dropping pill and preparation method thereof
WO2011072320A1 (en) * 2009-12-14 2011-06-23 Jubilent Global Limited Effervescent l-carnitine-based composition
EP2508179A1 (en) * 2011-04-05 2012-10-10 Lonza Ltd. Use of L-Carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function
CN102715394A (en) * 2012-07-09 2012-10-10 宣城柏维力生物工程有限公司 L-carnitine effervescent tablet
CN107319242A (en) * 2017-07-20 2017-11-07 郑州博凯医药保健品有限公司 L-cn effervescent tablet for slimming and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
庄越 等: "《实用药物制剂技术》", 31 January 1999, 北京：人民卫生出版社 *
谢秀琼: "《现代中药制剂新技术》", 30 June 2004, 北京：化学工业出版社 *

Similar Documents

Publication Publication Date Title
JP2021014467A (en) Nutritional composition
KR0180207B1 (en) Calcium and trace mineral supplements
CN106420643B (en) A kind of chewable tablets and preparation method thereof containing vitamine C sodium
US7932288B2 (en) Composition for relieving subjective symptoms of fatigue
US20080268038A1 (en) Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
US20150174088A1 (en) Food supplement containing alpha-keto acids for supporting diabetes therapy
CA2362344A1 (en) Composition for optimizing muscle performance during exercise
US7740878B2 (en) Use of betaine to enhance exercise performance
CN103918965A (en) Physical fatigue alleviating beverage
US20150246066A1 (en) Nutritional supplement
US10485836B2 (en) Anti-fatigue composition used for increasing endurance performance, and use of the same
EP2910131A1 (en) Anti-fatigue composition and use thereof
CN108606269B (en) Sports nutritional supplement and preparation method thereof
CN104546955A (en) Raw kiwifruit flavor vitamin C sodium buccal tablet and preparation process thereof
WO2015137387A1 (en) Muscle enhancing drug
KR101177888B1 (en) Composition for Relieving and Preventing Hangover
CN111990574A (en) L-carnitine nutritional effervescent tablet
US20010020007A1 (en) Vitamin preparations for reducing oxygen consumption during physical efforts
CN103110114B (en) Beta-alanine-containing composition for endurance increase, and preparation thereof
CN107439866A (en) Matrimony vine chickpea plant nutrients beverage and its preparation technology
CN109380728B (en) Composition and health food with auxiliary blood pressure lowering effect
CN106723027A (en) A kind of alimentation composition of resist oxygen lack and its application
CN112754018A (en) Vitamin bubble buccal tablet and preparation method thereof
CN104605223A (en) Original strawberry flavor vitamin C sodium buccal tablet and preparation process thereof
JPH05292918A (en) Functional health food

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20201127